Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
3.22(c) 3.08(c) 2.92(c) 2.75(c) 2.67(c) Last
651 314 434 184 347 719 457 887 520 865 Volume
-4.73% -4.35% -5.19% -5.82% -2.91% Change
More quotes
Estimated financial data (e) (USD)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Sales 2021 - - -
Net income 2021 -120 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,96x
Yield 2021 -
Capitalization 139 M 139 M -
EV / Sales 2020
Capi. / Sales 2021 -
Nbr of Employees 10
Free-Float 50,6%
More Financials
Company
Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic,... 
More about the company
All news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
01/20BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/20Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board..
GL
01/20Brooklyn ImmunoTherapeutics, Inc. Appoints Erin S. Enright and Heather B. Redman to its..
CI
01/13Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Prope..
AQ
01/05BROOKLYN IMMUNOTHERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities (for..
AQ
2021Cantor Fitzgerald Starts Brooklyn ImmunoTherapeutics at Overweight With $9 Price Target
MT
2021BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Brooklyn Immunotherapeutics, Inc. Announces Resignation of Luba Greenwood as Director E..
CI
2021Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA : BTX) added to NASDAQ Biotechnology Index
CI
2021Brooklyn ImmunoTherapeutics Added toáICE Biotechnology Index
AQ
2021Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index
AQ
2021Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
AQ
2021Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Qua..
GL
2021Brooklyn ImmunoTherapeutics, Inc. Appoints Susan McClatchey as Head of Quality
CI
More news
News in other languages on BROOKLYN IMMUNOTHERAPEUTICS, INC.
01/20Brooklyn ImmunoTherapeutics, Inc. nomme Erin S. Enright et Heather B. Redman à son cons..
2021Brooklyn Immunotherapeutics, Inc. annonce que Luba Greenwood a informé le conseil d'adm..
2021Brooklyn ImmunoTherapeutics propose un placement secondaire de 6,28 millions d'actions
2021Brooklyn Immunotherapeutics transfère la cotation de ses actions du NYSE American au Na..
2021Brooklyn ImmunoTherapeutics nomme Roger Sidhu directeur médical en chef
More news
Analyst Recommendations on BROOKLYN IMMUNOTHERAPEUTICS, INC.
More recommendations
Chart BROOKLYN IMMUNOTHERAPEUTICS, INC.
Duration : Period :
Brooklyn ImmunoTherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BROOKLYN IMMUNOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 2,67 $
Average target price 14,50 $
Spread / Average Target 443%
EPS Revisions
Managers and Directors
Howard J. Federoff President, Chief Executive Officer & Director
Sandra Gurrola Chief Financial Officers
Charles R. Cherington Director
Kevin A. D'Amour Chief Scientific Officer
Jay Sial Chief Administrative & Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
BROOKLYN IMMUNOTHERAPEUTICS, INC.-34.05%139
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508